Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brexit Good For UK Firms And Emerging Markets?

This article was originally published in PharmAsia News

Executive Summary

Despite creating shockwaves around the globe, the UK’s ‘Brexit’ vote to leave the EU is expected by analysts to positively impact European pharma companies such as GSK, Sanofi and AstraZeneca. But the impact on product sales and emerging markets will be more of a mixed bag.


Related Content

2016 Review: Pricing, R&D Issues Dominate China Commercial Arena
2016 Review: Rapid Change Defines China Regulatory Environment


Related Companies